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Circulating micrornas associated with glycemic
impairment and progression in Asian Indians
Elena Flowers1*, Meghana Gadgil2, Bradley E. Aouizerat1,3 and Alka M. Kanaya2,4
Abstract
Aims/hypothesis: Asian Indians have a high incidence of type 2 diabetes, but factors associated with glycemic
progression in this population are not understood. MicroRNAs are emerging as important mediators of glucose
homeostasis and have not been previously studied in Asian Indians. We examined microRNA (miR) expression
associated with glycemic impairment and progression in Asian Indians from the San Francisco Bay Area. We studied
128 Asian Indians age 45–84 years without known cardiovascular disease and not taking diabetes medications. Oral
glucose tolerance tests were performed at baseline and after 2.5 years. We quantified circulating miRs from plasma
collected during the enrollment visit using a flow cytometry-based assay.
Results: Glycemic impairment was present in 57 % (n = 73) at baseline. MiR-191 was positively associated with
glycemic impairment (odds ratio (OR) 1.7 (95 % CI 1.2, 2.4), p < 0.01). The prevalence of glycemic progression after
2.5 years was 24 % (n = 23). Six miRs were negatively associated with glycemic progression: miR-122 (OR 0.5 (0.2, 0.8),
p < 0.01), miR-15a (OR 0.6 (0.4, 0.9), p < 0.01), miR-197 (OR 0.6 (0.4, 0.9), p < 0.01), miR-320a (OR 0.6 (0.4, 0.9), p < 0.01),
miR-423 (OR 0.6 (0.4, 0.9), p < 0.01), and miR-486 (OR 0.5 (0.3, 0.8), p < 0.01). Further multivariate adjustment did not
attenuate these results.
Conclusions/interpretation: This is the first study to investigate circulating miRs associated with glycemic status
among this high-risk ethnic group. Individual miRs were significantly associated with both glycemic impairment and
glycemic progression. Further studies are needed to determine whether miR (s) might be useful clinical biomarkers for
incident T2D in the Asian Indian population.
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Introduction
Asian Indians in the United States have a disproportion-
ately higher prevalence (16–21 %) of type 2 diabetes melli-
tus (T2D) [1, 2] and associated metabolic conditions [3]
compared to other racial groups. The exact biological
mechanisms underlying risk in this population compared
to other racial/ethnic groups are not well understood.
Therefore approaches to risk reduction are limited
and show suboptimal efficacy. Current risk screening
approaches are limited to the detection of harmful meta-
bolic conditions (i.e., impaired glucose tolerance, impaired
fasting glucose). Identification of circulating biomarkers
that provide insight about the underlying pathophysiology
of T2D in Asian Indians, as well biomarkers associated
with incident T2D prior to the onset of impaired glucose
metabolism, may allow for earlier detection of the highest
risk patients and improved treatments.
MicroRNAs (miRs) are components of an epigenetic
mechanism regulating expression of messenger RNAs
(mRNAs). Structurally, miRs are 18–24 nucleotide
sequences that function by binding to a critical region
on mRNA molecules in order to prevent translation into
amino acids. More than 2,500 miRs have been identified
in humans [4] and approximately 300 of these have been
identified in the circulation from both cellular and non-
cellular origins. Measurement of miRs captures com-
bined genetic and environmental risk factors to provide
a more comprehensive picture of the etiology of
complex disease. Recent studies of primarily Caucasian
non-Hispanic populations identified differential expres-
sion of circulating miRs in individuals with T2D com-
pared to healthy controls [5–8]. MiR-126, which is
* Correspondence: elena.flowers@ucsf.edu
1Department of Physiological Nursing, School of Nursing, University of
California, 2 Koret Way #N605L, CA 94143 San Francisco, USA
Full list of author information is available at the end of the article
© 2015 Flowers et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain
Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
Flowers et al. Biomarker Research  (2015) 3:22 
DOI 10.1186/s40364-015-0047-y
active in endothelial cells, exhibits decreased expression
in Caucasian individuals who develop T2D after 10 years
compared to those who do not [8]. Cross-sectional stud-
ies of miR-126 identified lower expression in individuals
with glycemic impairment or T2D. Other studies reported
additional individual miRs (e.g., miR-140, miR-155 miR-
221, miR-222, miR-320a, miR-375, miR-532) [9, 5, 10–12]
that are differentially expressed in T2D and related condi-
tions. These findings support the possibility that circulating
miRs may provide novel insight about the biological mech-
anisms underlying T2D in Asian Indians and function
as predictors of incident T2D. This study sought to (1)
compare miR expression between Asian Indians with and
without prevalent glycemic impairment; and (2) to compare
miR expression between Asian Indians who had glycemic
progression over 2.5 years to those who remained stable.
Results
We studied 128 participants who were not taking diabetes
medications at study enrollment. Of these, 57 % (n = 73)
exhibited glycemic impairment (i.e., IGT, IFG, T2D).
There are more males in this group (29 % vs. 18 %) and
higher BMI (26.9 kg/m2 vs. 24.7 kg/m2) compared to indi-
viduals with normal glycemia (p < 0.01 for all, Table 1).
The cardiovascular risk profile was worse in the impaired
glycemia group with higher systolic (127 mmHg vs.
117 mmHg) and diastolic (75 mmHg vs. 69 mmHg) blood
pressure, lower HDL-cholesterol (47 mg/dL vs. 53 mg/
dL), and higher triglycerides (146 mg/dL vs. 115 mg/dL)
(p < 0.05 for all, Table 1). There were no differences in
total and LDL-cholesterol. Blood glucose (105 mg/dL vs.
87 mg/dL), insulin (15 μIU/mL vs. 10 μIU/ml), and
HOMA-IR (4.1 μIU/mL*mmol/L vs. 2.2 μIU/mL*mmol/L)
were all higher in the glycemic impairment group (p < 0.01
for all). Additional clinical characteristics were reported
previously [13].
Of the 94 participants evaluated after 2.5 years, 24 %
(n = 23) exhibited glycemic progression. There were no
statistically significant differences in baseline clinical
characteristics between those who did and did not have
incident glycemic impairment (Table 2). In paired ana-
lyses, we observed that blood glucose (91 mg/dL vs.
101 mg/dL), insulin (11.5 μIU/mL vs. 17.8 μIU/ml), and
HOMA-IR (2.6 μIU/mL*mmol/L vs. 4.5 μIU/mL*mmol/
L) increased after 2.5 years in the subset of participants
(n = 23) whose glycemic impairment worsened (Table 3).
However there were no significant changes in cardiovas-
cular risk factors, waist circumference, or BMI.
Of the thirty miRs measured, 6 (i.e., miR-138, miR-192,
miR-193b, miR-214, miR-370, miR-375) were below the
limit of detection (i.e., 10 AU) and failed to retain a mini-
mum of at least of two of three technical replicates for
every participant and were excluded from the analysis.
One of the remaining 24 miRs was significantly associated
with glycemic impairment at baseline. In unadjusted logis-
tic regression models, miR-191 (odds ratio (OR) 1.7 (1.2,
2.4)) was positively associated with glycemic impairment
(p < 0.05) (Table 4). In a multivariate adjusted model in-
cluding age, sex, BMI, and waist circumference, the odds
ratio remained statistically significant. Further adjustment
for HDL-cholesterol, triglycerides, and blood pressure did
not attenuate these effects.
Table 1 Baseline demographic and clinical characteristics in individuals with and without glycemic impairment at baseline
Characteristics Mean ± SD, Median (IQR), or n (%) Glycemic Impairment (n = 73) Normal Glycemia (n = 55) p-value
Sex (male) 29 (40) 18 (33) 0.002
Age (years) 56 ± 9 57 ± 7 0.897
Current Smokers 3 (4) 3 (5) 0.386
Physical Activity (MET-minutes/week) 1313 (585, 2940) 1365 (683, 2333) 0.942
Systolic Blood Pressure (mm Hg) 127 ± 15 117 ± 16 <0.001
Diastolic Blood Pressure (mm Hg) 75 ± 12 69 ± 9 0.002
Total Cholesterol (mg/dL) 191 ± 33 194 ± 31 0.683
LDL-c (mg/dL) 116 ± 31 117 ± 27 0.731
HDL-c (md/dL) 47 ± 13 53 ± 15 0.016
Triglycerides (mg/dL) 146 ± 72 115 ± 39 0.006
Fasting Blood Glucose (mg/dL) 105 ± 21 87 ± 6 <0.001
Insulin (μIU/mL) 15 ± 11 10 ± 5 0.001
HOMA-IR (μIU/mL*mmol/L) 4.1 ± 3.4 2.2 ± 1.1 <0.001
Body Mass Index (kg/m2) 26.9 ± 5.1 24.7 ± 3.6 0.006
Waist Circumference (cm) 98 ± 13 91 ± 11 0.003
cm centimeters, HDL-c high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment-insulin resistance, kg/m2 kg per meter2, LDL-c low density
lipoprotein cholesterol, mcU/mL microUnit per milliliter, mg/dL milligrams per deciliter, mm Hg millimeters of mercury, SD standard deviation
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Six miRs were significantly associated with glycemic
progression after 2.5 years. These included miR-122
(odds ratio (OR) 0.5 (95 % CI 0.2, 0.8)), miR-15a (OR 0.6
(0.4, 0.9)), miR-197 (OR 0.6 (0.4, 0.9)), miR-320a (OR 0.6
(0.4, 0.9)), miR-423 (OR 0.6 (0.4, 0.9)), and miR-486 (OR
0.5 (0.3, 0.8)), which were all inversely associated with
glycemic progression (p < 0.01 for all) (Table 4). We
adjusted for age, sex, and waist circumference and
observed the same significant association with glycemic
progression. We then added HDL-cholesterol, triglycer-
ides, and blood pressure to the model and observed the
same significant associations. Fold changes are presented
in Additional file 1: Table S1.
Discussion
To our knowledge, this is the first study to investigate
circulating miRs associated with glycemic impairment in
the high risk Asian Indian ethnic group. We evaluated
the association between circulating miRs and both
prevalent glycemic impairment and glycemic progression
after 2.5 years. We found a positive relationship between
miR-191 and the presence of glycemic impairment. Six
miRs (i.e., miR-122, miR-15a, miR-197, miR-320a, miR-
423, miR-486) were differentially expressed between the
subset of individuals who had incident glycemic impair-
ment after 2.5 years compared to those who remained
stable. All six miRs exhibited an inverse relationship
Table 2 Baseline demographic and clinical characteristics in individuals with progressive glycemic impairment compared to no
change at 2.5 years
Characteristics Mean ± SD, Median (IQR), or n (%) Progressive Glycemic Impairment (n = 23) No Change (n = 71) p-value
Sex (male) 14 (61) 41 (58) 0.070
Age (years) 55 ± 9 57 ± 9 0.310
Current Smoking 8 (9) 3 (4) 0.705
Physical Activity (MET-minutes/week) 1260 (473, 2100) 1470 (613, 2940) 0.293
Systolic Blood Pressure (mm Hg) 119 ± 20 122 ± 17 0.420
Diastolic Blood Pressure (mm Hg) 71 ± 13 71 ± 10 0.942
Total Cholesterol (mg/dL) 188 ± 39 188 ± 29 0.955
LDL-c (mg/dL) 113 ± 33 112 ± 27 0.872
HDL-c (md/dL) 51 ± 16 50 ± 14 0.780
Triglycerides (mg/dL) 120 ± 65 126 ± 56 0.676
Fasting Blood Glucose (mg/dL) 91 ± 8 91 ± 11 0.813
Insulin (μIU/mL) 11.5 ± 6.2 11.5 ± 6.2 0.807
HOMA-IR (μIU/mL*mmol/L) 2.6 ± 1.5 2.8 ± 2.1 0.715
Body Mass Index (kg/m2) 25.7 ± 4.7 25.9 ± 4.5 0.878
Waist Circumference (cm) 93 ± 12 94 ± 12 0.856
cm centimeters, HDL-c high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment-insulin resistance, kg/m2 kg per meter2, LDL-c low density
lipoprotein cholesterol, mcU/mL microUnit per milliliter, mg/dL milligrams per deciliter, mm Hg millimeters of mercury, SD standard deviation
Table 3 Change in clinical characteristics in individuals with progressive glycemic impairment after 2.5 years (n = 23)
Characteristics Mean ± SD or n (%) Baseline Follow up (2.5 Years) p-value
Systolic Blood Pressure (mm Hg) 119 ± 20 123 ± 13 0.235
Diastolic Blood Pressure (mm Hg) 71 ± 13 76 ± 13 0.081
Total Cholesterol (mg/dL) 188 ± 39 184 ± 30 0.364
LDL-c (mg/dL) 113 ± 33 106 ± 26 0.091
HDL-c (md/dL) 51 ± 16 51 ± 20 0.895
Triglycerides (mg/dL) 120 ± 65 137 ± 69 0.211
Fasting Blood Glucose (mg/dL) 91 ± 8 101 ± 18 0.008
Insulin (μIU/mL) 11.5 ± 6.2 17.8 ± 6.6 <0.001
HOMA-IR (μIU/mL*mmol/L) 2.6 ± 1.5 4.5 ± 2.1 <0.001
Body Mass Index (kg/m2) 25.7 ± 4.7 26.3 ± 4.9 0.065
Waist Circumference (cm) 93 ± 12 94 ± 13 0.796
cm centimeters, HDL-c high density lipoprotein cholesterol, HOMA-IR homeostasis model assessment-insulin resistance, kg/m2 kg per meter2, LDL-c low density
lipoprotein cholesterol, mcU/mL microUnit per milliliter, mg/dL milligrams per deciliter, mm Hg millimeters of mercury, SD standard deviation
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with odds for glycemic progression. The addition of clin-
ical covariates (i.e., age, sex, waist circumference, HDL-
cholesterol, triglycerides) to logistic regression models
did not meaningfully attenuate the association for either
glycemic impairment or glycemic progression.
Asian Indians living in the United States have a high
prevalence of T2D and related risk factors [3, 14, 1] and
the prevalence is increasing drastically in India and other
parts of South Asia [15, 16]. While there are some known
common risk factors for T2D in this population (i.e., diet,
sedentary lifestyle, genetic predisposition), the full etiology
is not well understood and therefore approaches to risk
reduction have been limited. Identification of circulating
miRs associated with glycemic impairment has the poten-
tial to provide novel information about the mechanisms
underlying T2D. Further, there is the possibility for detec-
tion of homogeneous subgroups of individuals at risk
based on commonalities in miR expression. In addition,
miRs may be useful biomarkers to identify individuals at
highest risk for developing T2D who might benefit from
aggressive prevention measures.
MiR-486 is inversely associated with risk for glycemic
progression. We previously identified that this miR is posi-
tively associated with insulin resistance and response to
thiazolidenidones, which improve insulin sensitivity, in a
multiracial sample [17]. MiR-486 is enriched in muscle
tissue where it targets phosphatase and tensin homolog
(PTEN) and forkhead box O1a (FOXO1A) and regulates
muscle growth and atrophy in mice [18, 19]. In other
tissues, PTEN is implicated in insulin signaling and cellular
glucose uptake. Inhibition of PTEN decreases blood glucose
in rats [20] and mutations in PTEN in humans are associ-
ated with insulin sensitivity and glucose tolerance [21].
Peroxisome proliferator-activated receptor γ (PPAR- γ), the
primary target of thiazolidenidones, upregulates PTEN,
which may lead to changes in insulin sensitivity and blood
glucose [22].
MiR-486 has also been implicated in other diseases.
Findings from these studies implicate potential mRNAs
and biologic pathways targeted by miR-486 that are rele-
vant to a regulatory role in development of risk for T2D.
In lung cancer, miR-486 regulates the insulin growth factor
signaling pathway by targeting insulin-like growth factor 1
(IGF1), IGF1 receptor (IGF1R), and phosphoinositide-3-
kinase, regulatory subunit 1 (alpha) (PIK3R1) [23]. Two
prior studies identified low levels of miR-486 in hepatocel-
lular carcinoma cells (HCC) from human biopsy samples
and HCC lines in vitro. Functional targets of miR-486 in
HCC include PIK3R1 [24] and rho-interacting serine/threo-
nine kinase (CITRON) and claudin 10 (CLDN10) [25].
MiR-122, which was negatively associated with glycemic
progression in our study and appears to be a target of
PPAR- γ [26], is the primary hepatic miR and regulates
progression of HCC [27]. Whether miR-486 and miR-
122 are co-expressed in hepatocytes and may have
related functions in insulin and glucose metabolism in
liver or other tissues is not known. Further functional
studies are needed to determine if the pathways regu-
lated by miR-486 in other diseases might also be rele-
vant to the development of T2D.
In addition to HCC, associations between miR-122 and
other hepatic diseases, including hepatitis, have been well
described [28, 29]. Data from in vitro studies of hepatic
cell lines provide evidence for regulation of hepatic lipid
metabolism by miR-122 [30], however our prior study [31]
and others [11] found a low level of this miR in individuals
free from serious hepatic disease using quantitative poly-
merase chain reaction-based quantitation.
We found that miR-15 was decreased in individuals
who had glycemic progression after 2.5 years. MiR-15a
Table 4 Odds ratios for microRNA expression associated with glycemic impairment
Unadjusted Model 1* Model 2**
OR€ 95 % CI p-value OR€ 95 % CI p-value OR€ 95 % CI p-value
Prevalent Glycemic Impairment
hsa-miR-191-5p 1.7 1.2, 2.4 0.002 1.6 1.1, 2.3 0.014 1.5 1.1, 2.2 0.026
Progressive Glycemic
Impairment After 2.5 Years
hsa-miR-122-5p 0.5 0.2, 0.8 0.003 0.4 0.3, 0.8 0.003 0.5 0.3, 0.8 0.003
hsa-miR-15a-5p 0.6 0.4, 0.9 0.040 0.6 0.4, 0.9 0.031 0.6 0.4, 0.9 0.034
hsa-miR-197-3p 0.6 0.4, 0.9 0.020 0.6 0.4, 0.9 0.016 0.6 0.4, 0.9 0.018
hsa-miR-320a 0.6 0.4, 0.9 0.038 0.6 0.4, 0.9 0.045 0.6 0.4, 0.9 0.032
hsa-miR-423-5p 0.6 0.4, 0.9 0.033 0.6 0.4, 0.9 0.039 0.6 0.4, 0.9 0.030
hsa-miR-486-5p 0.5 0.3, 0.8 0.004 0.4 0.3, 0.8 0.003 0.4 0.3, 0.8 0.003
CI confidence interval, MET metabolic equivalent
€microRNAs are scaled by quartile
*Model 1 adjusted for age, sex, and waist circumference
**Model 2 adjusted for variables in Model 1 and HDL-cholesterol and triglycerides
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was also decreased in the study of prevalent T2D after
10 years in a Caucasian sample [8]. One in vitro study
found that miR-15 is increased after 1-h of exposure to
glucose but decreased with long-term exposure and may
mediate B-cell function and insulin biosynthesis by
targeting uncoupling protein-2 (UCP-2) [32]. Several
additional studies support a critical role of miR-15a in
endothelial cell function and angiogenesis in peripheral
vascular, myocardial, and cerebrovascular tissue [33–36].
MiR-15 is increased in the serum of diabetic patients
with critical limb ischemia and decreases angiogenesis in
pro-angiogenic cells in vitro by targeting vascular endo-
thelial growth factor A (VEGFA) [34]. Increased levels of
miR-15 are associated with myocardial ischemia/reperfu-
sion injury in mice [33] and suppression of miR-15 by
PPAR-γ in cerebral vascular endothelial cells increases
pro-angiogenic activity in animal models and in vitro
studies [35]. We found decreased expression of miR-15
prior to the onset of T2D, which corresponds with pro-
angiogenic activity according to data from functional
studies. Further research is needed to determine whether
there are mechanisms to protect from the long-term
vascular consequences of T2D early in the course of the
disease.
Consistent with our findings, one prior study identified
decreased miR-423 in individuals with T2D and or obesity
compared to normal weight non-diabetics [5]. In the same
study, neither insulin or treatment with metformin and
associated weight loss were associated with any changes
in miR-423, though this miR is highly correlated with
measures of insulin sensitivity [5]. Only one other study
reporting significant findings for miR-423 was identified.
In an in vitro model of HCC, miR-423 is up-regulated and
targets the tumor suppressor gene p21Cip1/Waf1 facilitat-
ing oncogenesis [37].
MiR-320, which was decreased in our study, appears
to also be enriched in endothelial cells and respond to
oxidative stress to regulate cell migration and proliferation
[38–41]. Predicted targets of miR-320a from functional
studies include IGF1R, polycomb ring finger oncogene
(BMI-1), heme-oxygenase 1 (HO-1), glutathione cysteine
ligase modifying subunit (GCLM) and oxidative stress
induced growth inhibitor 1 (OKL38) and VEGF. Up-
regulation of miR-320a results in decreased negative
responses to oxidative stress [40, 41] and decreased cellu-
lar migration and tumor invasion [38, 39].
Little is known about the function of miR-197. This miR
is computationally predicted to target several hundred
possible mRNAs, including targets associated with type 2
diabetes (e.g., glucagon (GCG), deiodinase, iodothyronine,
type II (DIO2), leptin (LEP), NK2 homeobox 2 (NKX2-2),
solute carrier family 30, member 8 (SLC30A8), synapsin I
(SYN1), nuclear respiratory factor 1 (NRF1), SHC trans-
forming protein 1 (SHC1), Kruppel-like factor 12 (KLF12),
protein kinase C, beta (PRKCB) [42, 43]. Further studies
are needed to refine the list of possible mRNA targets and
determine the biologic pathways regulated by this miR.
MiR-320a and miR-486 were decreased in individuals
who exhibited glycemic progression after 2.5 years. By
contrast, our prior study showed a direct relationship with
prevalent insulin resistance [17]. The apparent discrep-
ancy in these findings may be the result of the time point
at which miRs were measured relative to the progression
of disease. In the prior study, we included individuals with
confirmed insulin resistance but no diabetes, whereas in
this study, we compared individuals who were further
along the glycemic spectrum than having isolated insulin
resistance without any glycemic impairment. A recent
meta-analysis of miRs associated with type 2 diabetes
identified similar inconsistencies between studies [11].
Future longitudinal studies relating changes in miRs and
progression to T2D are needed in order to understand
whether individual miRs are the cause or the consequence
of glycemic impairment. A second possible explanation is
that our prior study included a multi-racial sample,
whereas this study included only Asian Indians.
MiR-126 was associated with risk for type 2 diabetes
after 10-years in a primarily Caucasian sample [8], but in
our study this miR was one of the least variable and was
selected as a normalizer. Similarly to above, possible ex-
planations include the time course of disease compared
to when the microRNAs were measured and differences
in disease mechanisms between Asian Indians and other
racial groups.
The specific biologic mechanisms underlying glycemic
impairment and T2D vary between groups and individuals.
Identification of circulating miR biomarkers has the possi-
bility to provide information about the specific causal path-
ways for an individual or group of individuals. Functional
studies are needed to identify and validate the exact mRNA
targets of the miRs that are differentially expressed in Asian
Indians with prevalent or incident glycemic impairment
compared to healthy individuals. Future clinical implica-
tions include optimization of treatments to target relevant
biologic pathways and identification of new pharmacologic
targets. Further studies with larger sample sizes and longer
follow up are needed to validate the findings for miRs
reported here and determine whether there is a set of miRs
that significantly improve prodromal risk prediction.
Finally, comparisons of circulating miR expression between
Asian Indians and other racial groups will provide insight
into similarities and differences in the etiology of T2D with
future implications for treatments.
There are limitations to this study worthy of consider-
ation. Standardized approaches to normalization of miR
expression data from plasma and serum samples are not
established. However, consensus is building around
normalization approaches that average signals from
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multiple miRs [44–47]. We used the geNorm algorithm to
select the set of three miRs that showed low variability in
our sample. These included miR-126, miR-21, and miR-24.
Interestingly, miR-126, which showed very little variability
in our sample, was previously associated with risk for T2D
after 10 years in a primarily Caucasian sample [8]. In a prior
study, we showed that MiR-21 is associated with athero-
genic dyslipidemia in South Asian men [31]. This miR is
also well established in inflammatory pathways [48]. The
incongruity of our findings compared with previous stud-
ies supports the need to establish standards for data
normalization and other methodologic considerations in
order to compare findings between studies. Another limi-
tation of this study is the selection of the subset of miRs
for which there was some a priori evidence to suggest a
functional role in glucose metabolism. Future studies
should incorporate an agnostic approach to miR detection
in order to identify novel targets related to risk for T2D.
We identified individual circulating miRs associated
with prevalent glycemic impairment and glycemic pro-
gression in the high risk Asian Indian population. Among
these are several miRs that have previously been associ-
ated with T2D and related conditions in other studies, as
well as miRs that are predicted to be implicated in bio-
logically relevant pathways. This is promising evidence to
suggest that circulating miRs may be useful for identifica-
tion of the biologic mechanisms underlying T2D in Asian
Indians. Implications include optimization of treatment
approaches and new treatment targets. Additional poten-
tial clinical applications include improved detection of
glycemic impairment and identification of individuals at
high risk for progression to T2D.
Methods
Study design, sample, and clinical data collection
We studied participants in the Metabolic syndrome in
Asian Indians Living in America (MASALA) Study [13].
Briefly, this is a sample of community-dwelling adults who
self-identify as Asian Indian and were free from known
cardiovascular disease at baseline. Of 150 participants in
the MASALA study, 149 provided complete baseline data.
We excluded 21 participants taking diabetes medications at
baseline for a sample size for evaluation of prevalent
glycemic impairment of 128. After 2.5 years of follow-up,
112 participants completed a second clinical examination.
Of these, we excluded 18 participants who had T2D at
baseline for a sample size of 94 in the follow-up visit.
Participants were sampled by surname from all counties in
the San Francisco Bay Area as described previously [13].
Demographic information was collected by self-report.
Height, weight, waist circumference, and blood pressure
were collected by trained study personnel [13]. Physical
activity was assessed using the Typical Week’s Physical
Activity Questionnaire [49]. Participants were administered
75 g oral glucose and blood glucose measurements were
obtained after 120 min. Impaired glucose tolerance (IGT)
was defined as 2-h glucose 140–199 mg/dl, impaired fasting
glucose (IFG) was defined as fasting glucose 100–125 mg/
dl, and T2D was defined as 2-h glucose ≥200 mg/dl, or fast-
ing glucose ≥126 mg/dl. Glycemic impairment was defined
as the presence of IGT, IFG, or T2D at baseline. Glycemic
progression was defined as (1) progression from normal
glycemia to IGT, IFT, or T2D; (2) from IGT to IFG or T2D;
or (3) from IFG to T2D after 2.5 years of follow-up. Body
mass index (BMI) was calculated using the formula kilo-
grams/meters2. To estimate insulin sensitivity we calculated
homeostasis –model assessment of insulin resistance
(HOMA-IR) using the formula I0 (μIU/mL) * G0 (mmol/
L)/22.5 [50]. Blood used for banking of plasma was col-
lected at baseline into vacutainers containing the preser-
vative EDTA, centrifuged at 4 °C to separate plasma
from cellular blood components, and stored at −80 °C.
The study was approved by the University of California,
San Francisco Institutional Review Board.
Molecular data collection
We selected a panel of 28 miRs (i.e., miR-122-5p, miR-126-
3p, miR-138-5p, miR-140-5p, miR-146a-5p, miR-146b-5p,
miR-15a-5p, miR-150-5p, miR-191-5p, miR-192-5p, miR-1
93b-3p, miR-195-5p, miR-197-3p, miR-20b-5p, miR-21-59,
miR-222-3p, miR-223-3p, miR-24-3p, miR-27a-3p, miR-2
9b-3p, miR-320a, miR-33a-3p, miR-33b-5p, miR-370-3p,
miR-375, miR-423-5p, miR-486-5p, miR-503-5p) to meas-
ure based on previous data from human studies of blood-
based expression of miRs in T2D and related conditions.
Two miRs (i.e., miR-214-3p, miR-22-3p) were selected as
potential normalizers. MicroRNAs were quantified using
the Firefly Circulating miRNA Assay (Firefly BioWorks,
Cambridge, MA) providing direct detection of microRNAs
from plasma without isolation [51]. MiRs from plasma were
hybridized to complementary oligonucleotides covalently
attached to encoded hydrogel microparticles. The bound
target was ligated to oligonucleotide adapter sequences that
serve as universal PCR priming sites. The miR-adapter
hybrid molecules were then denatured from the particles at
95 °C and reverse transcription polymerase chain reaction
(RT-PCR) was performed using a fluorescent forward
primer. Once amplified, the fluorescent target was rehybri-
dized to the original capture particles and scanned on a
EMD Millipore Guava 8HT Flow Cytometer (Merck KGaA
Darmstadt, Germany). This assay exhibits 90–92 % con-
cordance with other quantitation assays [52] and has been
used in previous studies published in peer-reviewed jour-
nals [53–55, 17]. Three technical replicate measurements
were obtained for each sample and miR target. MiRs that
failed to retain at least two of three technical replicates with
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a robust enough signal for analysis (i.e., 10 AU) for each
sample were excluded from analysis.
Statistical analysis
Student’s t-tests, Pearson’s chi-squared tests, and Wilcoxon
rank sum tests were used to compare demographic charac-
teristics between groups and paired samples t-test were
used to compare the sample over time. Normalized expres-
sion of each sample for each miR target was calculated
using the geometric mean expression of three miRs (i.e.,
miR-126-3p, miR-21-5p, miR-24-3p) selected using the
geNorm algorithm [45]. Logistic regression models were
used to determine odds ratios with sequential adjustment
for covariates. MiRs were log transformed for logistic
regression models. Fold change differential expression of
miRs between groups was calculated as the ratio of normal-
ized expression in the group with prevalent glycemic im-
pairment or glycemic progression compared to those who
were normoglycemic or stable, respectively. Wilcoxon rank
sum tests were used to compare normalized expression of
miRs between groups (α = 0.05). We used a permutation
test to control for the family-wise error rate (FWER) across
all miRs.
Additional file
Additional file 1: Table S1. Fold Change MicroRNA Expression.
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